BioClean BarrierPlus™ Sterile Gauntlet - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BioClean BarrierPlus™ Sterile Gauntlets (S-BBNG) are designed for use in highly controlled environments setting the standard for cleanliness and quality assurance.

Processed in an ISO Class 4 Cleanroom, BioClean BarrierPlus gauntlets have incredibly low levels of particulates and are packed in cleanroom compatible EasyTear™ packaging. Manufactured from white-coloured accelerator-free nitrile (a stretchy, synthetic rubber), they are resistant to a wide range of chemicals, including a selection of commonly-used chemotherapy drugs.  Nitrile also exhibits excellent ESD (Electrostatic Dissipative) properties.

Each BioClean BarrierPlus gauntlet is visually inspected for holes on five separate occasions throughout the manufacturing process, along with water and air pressure testing, to guarantee delivery of a gauntlet 100% free from holes.

BioClean BarrierPlus™ Sterile Gauntlets are available in lengths of up to 840mm (33”) and three port sizes from 150mm to 300mm (6.0” to 12”). 

Also available from the BioClean BarrierPlus range is a sterile mitten (S-BBNM) for use when interventions are rare and access speed is critical, and a sleeve (S-BBNS0) available in lengths of up to 660mm (26”), and suitable for port sizes from 150mm (6.0”) to 300mm (12”).  With a cuff diameter of 90mm (3.5”) the sleeves will fit the majority of available cuff ring systems.

Contact Details:
Nitritex Ltd
Minton Enterprise Park, Oaks Drive
Newmarket, Suffolk, CB8 7YY
www.bioclean.com, info@bioclean.com

Tel: +44 1638 663338
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here